~~<i id='4A3C3BEC64'><strike id='4A3C3BEC64'><tt id='4A3C3BEC64'><pre id='4A3C3BEC64'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-09-29 08:29:33 Page View：84

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures
Next article： Affirmative action in medical school literally saved lives

explore

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

ARCH Venture Partners is raising $3 billion for a life sciences fund

AdobeARCHVenturePartners,oneofthetopinvestorsinthebiotechecosystem,israising$3billionforanewfund.The

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

The lessons of Aduhelm, an Alzheimer's drug that was not to be

StevenSenn/APAduhelm,apioneeringtreatmentforAlzheimer’sdiseasethatcollapsedundercorporatemistakesand